Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.

ABSTRACT: The use of antibodies in therapy and diagnosis has undergone an unprecedented expansion during the past two decades. This is due in part to innovations in antibody engineering that now offer opportunities for the production of "second generation" antibodies with multiple specificities or altered valencies. The targeting of individual components of the human epidermal growth factor receptor (HER)3-PI3K signaling axis, including the preferred heterodimerization partner HER2, is known to have limited anti-tumor effects. The efficacy of antibodies or small molecule tyrosine kinase inhibitors (TKIs) in targeting this axis is further reduced by the presence of the HER3 ligand, heregulin. To address these shortcomings, we performed a comparative analysis of two distinct approaches toward reducing

SUBMITTER: Kang JC 

PROVIDER: S-EPMC3984324 | biostudies-literature | 2014 Mar-Apr

REPOSITORIES: biostudies-literature